Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
EC grants conditional marketing authorization for Gilead's Veklury for COVID-19 » 11:14
07/03/20
07/03
11:14
07/03/20
11:14
GILD

Gilead

$76.31 /

+0.28 (+0.37%)

Gilead Sciences announced…

Gilead Sciences announced that the European Commission has granted conditional marketing authorization for Veklury, or remdesivir, as a treatment for SARS-CoV-2 infection, the virus that causes COVID-19. The conditional marketing authorization was granted in the interest of public health due to the COVID-19 pandemic and was based on a rolling review of supporting data that began in April 2020. Under this authorization, Veklury is indicated for the treatment of COVID-19 in adults and adolescents, aged 12 years and older and weighing at least 40 kg, with pneumonia requiring supplemental oxygen. Ongoing clinical trials continue to evaluate the safety and efficacy of remdesivir, including studies of remdesivir in combination with anti-inflammatory medicines and in special populations including pediatric patients. Research is also being conducted on new, investigational formulations of remdesivir that may enable studies of remdesivir in earlier stages of disease. "We appreciate the European Medicines Agency's rapid review of remdesivir in recognition of the unprecedented nature of this pandemic. This conditional marketing authorization is an important step forward as we work together to address the treatment needs of patients across Europe," said Merdad Parsey, MD, PhD, Chief Medical Officer, Gilead Sciences.

ShowHide Related Items >><<
GILD Gilead
$76.31 /

+0.28 (+0.37%)

GILD Gilead
$76.31 /

+0.28 (+0.37%)

06/30/20 SVB Leerink
Gilead's remdesivir price gives confidence in revenue, says SVB Leerink
06/30/20 Wells Fargo
Remdesivir pricing 'a responsible public health decision,' says Wells Fargo
06/29/20 Piper Sandler
Piper says Gilead sale to HHS should make remdesivir opportunity 'more tangible'
06/29/20 RBC Capital
RBC says HIV, other franchises more critical drivers of Gilead than remdesivir
GILD Gilead
$76.31 /

+0.28 (+0.37%)

GILD Gilead
$76.31 /

+0.28 (+0.37%)

GILD Gilead
$76.31 /

+0.28 (+0.37%)

GILD Gilead
$76.31 /

+0.28 (+0.37%)

Wednesday
Periodicals
EU in talks to reserve doses of Gilead's remdesivir, FT reports » 18:20
07/01/20
07/01
18:20
07/01/20
18:20
GILD

Gilead

$76.03 /

-0.93 (-1.21%)

The European Commission…

The European Commission in discussions with Gilead to reserve doses of its remdesivir drug to combat COVID-19 after the U.S. said it had purchased much of the global supply, the Financial Times' Michael Peel and Donato Paolo Mancini report. Stella Kyriakides, health commissioner for the EU, has held a series of talks with the pharma company, including over its production capacity, the authors say. "Commissioner Kyriakides has been in multiple discussions with the manufacturer, Gilead, including on their production capacity," the commission said. "The commission is also currently in negotiations with Gilead to reserve doses of remdesivir for EU member states." Reference Link

ShowHide Related Items >><<
GILD Gilead
$76.03 /

-0.93 (-1.21%)

GILD Gilead
$76.03 /

-0.93 (-1.21%)

06/30/20 SVB Leerink
Gilead's remdesivir price gives confidence in revenue, says SVB Leerink
06/30/20 Wells Fargo
Remdesivir pricing 'a responsible public health decision,' says Wells Fargo
06/29/20 Piper Sandler
Piper says Gilead sale to HHS should make remdesivir opportunity 'more tangible'
06/29/20 RBC Capital
RBC says HIV, other franchises more critical drivers of Gilead than remdesivir
GILD Gilead
$76.03 /

-0.93 (-1.21%)

GILD Gilead
$76.03 /

-0.93 (-1.21%)

GILD Gilead
$76.03 /

-0.93 (-1.21%)

GILD Gilead
$76.03 /

-0.93 (-1.21%)

Tuesday
Recommendations
Gilead's remdesivir price gives confidence in revenue, says SVB Leerink » 09:09
06/30/20
06/30
09:09
06/30/20
09:09
GILD

Gilead

$74.56 /

+0.04 (+0.05%)

SVB Leerink analyst…

SVB Leerink analyst Geoffrey Porges raised the firm's price target on Gilead to $95 from $94 and keeps an Outperform rating on the shares. The analyst notes that Gilead announced the "long-anticipated" remdesivir pricing for the developed world and the pricing "both exceeded and fell short" his price expectations. Porges is also increasing his revenue forecasts for remdesivir based on the company's increased supply and the higher pricing in ex U.S. markets. His new revenue forecast for Gilead is more than 40% above recent consensus for 2020-2023. While the analyst's revenue forecast for remdesivir increases by $800M-$1.8B in each of the next three years, his profit and earnings contributions increase less due to his cautious margin outlook.

ShowHide Related Items >><<
GILD Gilead
$74.56 /

+0.04 (+0.05%)

GILD Gilead
$74.56 /

+0.04 (+0.05%)

06/30/20 Wells Fargo
Remdesivir pricing 'a responsible public health decision,' says Wells Fargo
06/29/20 Piper Sandler
Piper says Gilead sale to HHS should make remdesivir opportunity 'more tangible'
06/29/20 RBC Capital
RBC says HIV, other franchises more critical drivers of Gilead than remdesivir
06/29/20 Piper Sandler
Gilead pricing for Remdesivir 'perfectly reasonable,' says Piper Sandler
GILD Gilead
$74.56 /

+0.04 (+0.05%)

GILD Gilead
$74.56 /

+0.04 (+0.05%)

GILD Gilead
$74.56 /

+0.04 (+0.05%)

GILD Gilead
$74.56 /

+0.04 (+0.05%)

Recommendations
Remdesivir pricing 'a responsible public health decision,' says Wells Fargo » 07:26
06/30/20
06/30
07:26
06/30/20
07:26
GILD

Gilead

$74.56 /

+0.04 (+0.05%)

Wells Fargo analyst Jim…

Wells Fargo analyst Jim Birchenough maintains an Equal Weight rating on shares of Gilead Sciences following pricing decision on remdesivir for severe COVID-19. Overall, the analyst views pricing below the high end of ICER recommendation as representing "a responsible public health decision." However, he remains uncertain on longer term commercial opportunity beyond 1.5M donated doses and $1B COGS in 2020 in the context of emerging competition and potential vaccine progress.

ShowHide Related Items >><<
GILD Gilead
$74.56 /

+0.04 (+0.05%)

GILD Gilead
$74.56 /

+0.04 (+0.05%)

06/29/20 Piper Sandler
Piper says Gilead sale to HHS should make remdesivir opportunity 'more tangible'
06/29/20 RBC Capital
RBC says HIV, other franchises more critical drivers of Gilead than remdesivir
06/29/20 Piper Sandler
Gilead pricing for Remdesivir 'perfectly reasonable,' says Piper Sandler
06/29/20 B. Riley FBR
Durect should be bought on weakness from Gilead termination, says B. Riley FBR
GILD Gilead
$74.56 /

+0.04 (+0.05%)

GILD Gilead
$74.56 /

+0.04 (+0.05%)

GILD Gilead
$74.56 /

+0.04 (+0.05%)

GILD Gilead
$74.56 /

+0.04 (+0.05%)

Monday
On The Fly
Fly Intel: Wall Street's top stories for Monday » 16:38
06/29/20
06/29
16:38
06/29/20
16:38
BA

Boeing

$194.42 /

+24.51 (+14.43%)

, SBUX

Starbucks

$73.50 /

+1.95 (+2.73%)

, KO

Coca-Cola

$44.35 /

+0.77 (+1.77%)

, F

Ford

$6.02 /

+0.11 (+1.86%)

, ADDYY

Adidas

$0.00 /

+ (+0.00%)

, FB

Facebook

$220.70 /

+4.84 (+2.24%)

, MSFT

Microsoft

$198.49 /

+2.24 (+1.14%)

, BBY

Best Buy

$86.31 /

+1.58 (+1.86%)

, GILD

Gilead

$74.56 /

+0.04 (+0.05%)

, ICPT

Intercept

$46.66 /

-30.9 (-39.84%)

, HRTX

Heron Therapeutics

$14.26 /

-5.555 (-28.04%)

, AMZN

Amazon.com

$2,682.00 /

-11.16 (-0.41%)

, AMC

AMC Entertainment

$4.43 /

+0.27 (+6.49%)

, IDEX

Ideanomics

$2.06 /

+0.61 (+42.07%)

, KNSA

Kiniksa

$26.00 /

+2.96 (+12.85%)

, BYND

Beyond Meat

$131.52 /

-10.16 (-7.17%)

Stocks saw a rebound from…

Open Full Text

ShowHide Related Items >><<
SBUX Starbucks
$73.50 /

+1.95 (+2.73%)

MSFT Microsoft
$198.49 /

+2.24 (+1.14%)

KO Coca-Cola
$44.35 /

+0.77 (+1.77%)

KNSA Kiniksa
$26.00 /

+2.96 (+12.85%)

IDEX Ideanomics
$2.06 /

+0.61 (+42.07%)

ICPT Intercept
$46.66 /

-30.9 (-39.84%)

HRTX Heron Therapeutics
$14.26 /

-5.555 (-28.04%)

GILD Gilead
$74.56 /

+0.04 (+0.05%)

FB Facebook
$220.70 /

+4.84 (+2.24%)

F Ford
$6.02 /

+0.11 (+1.86%)

BYND Beyond Meat
$131.52 /

-10.16 (-7.17%)

BBY Best Buy
$86.31 /

+1.58 (+1.86%)

BA Boeing
$194.42 /

+24.51 (+14.43%)

AMZN Amazon.com
$2,682.00 /

-11.16 (-0.41%)

AMC AMC Entertainment
$4.43 /

+0.27 (+6.49%)

ADDYY Adidas
$0.00 /

+ (+0.00%)

BA Boeing
$194.42 /

+24.51 (+14.43%)

06/26/20
Fly Intel: Top five analyst downgrades
06/26/20 RBC Capital
Spirit AeroSystems initiated with an Outperform at RBC Capital
06/26/20 Bernstein
Boeing downgraded to Market Perform from Outperform at Bernstein
06/25/20
Fly Intel: Top five analyst downgrades
SBUX Starbucks
$73.50 /

+1.95 (+2.73%)

06/24/20 JPMorgan
Starbucks price target raised to $78 from $73 at JPMorgan
06/15/20
Fly Intel: Top five analyst initiations
06/15/20 Atlantic Equities
Starbucks initiated with an Overweight at Atlantic Equities
06/11/20
Fly Intel: Top five analyst downgrades
KO Coca-Cola
$44.35 /

+0.77 (+1.77%)

06/17/20 Jefferies
Nestle home-office water business would be a fit for Primo Water, says Jefferies
05/28/20 Credit Suisse
Boston Beer downgraded to Neutral on valuation at Credit Suisse
05/18/20 Guggenheim
Guggenheim raises PepsiCo to 'Best Idea' in Food and Beverage, ups target
05/11/20 Citi
Monster Beverage downgraded to Neutral from Buy at Cit
F Ford
$6.02 /

+0.11 (+1.86%)

06/25/20 Morgan Stanley
Talks with Ford dealer highlight inventory risk, says Morgan Stanley
06/24/20 Morgan Stanley
GM electric vehicle business could be worth $100B, says Morgan Stanley
06/19/20 JPMorgan
Ford price target raised to $7 from $6 at JPMorgan
06/18/20 Jefferies
Jefferies raises price targets for Ford, GM and FCA on balance sheet de-risking
ADDYY Adidas
$0.00 /

+ (+0.00%)

06/26/20 KeyBanc
Gap partnership with Kanye West should help with younger shoppers, says KeyBanc
04/28/20 JPMorgan
Adidas price target lowered to EUR 215 from EUR 220 at JPMorgan
04/28/20 RBC Capital
Adidas price target lowered to EUR 230 from EUR 245 at RBC Capital
04/28/20 Morgan Stanley
Adidas price target lowered to EUR 195 from EUR 200 at Morgan Stanley
FB Facebook
$220.70 /

+4.84 (+2.24%)

06/30/20 Morgan Stanley
Morgan Stanley says buy Facebook amid boycott-driven weakness
06/30/20 Citi
Facebook shares overreacting to pause in ad spending, says Citi
06/29/20 Stifel
Stifel says Facebook sales won't be materially hurt unless ad boycott broadens
06/29/20 JPMorgan
Facebook estimates not at risk from ad boycott, says JPMorgan
MSFT Microsoft
$198.49 /

+2.24 (+1.14%)

06/29/20 JMP Securities
ZoomInfo initiated with a Market Perform at JMP Securities
06/24/20 Bernstein
Potential spinoff would be largely positive for VMware, says Bernstein
06/24/20 Baird
Ping Identity initiated with a Neutral at Baird
06/24/20 Argus
Microsoft price target raised to $235 from $200 at Argus
BBY Best Buy
$86.31 /

+1.58 (+1.86%)

06/23/20 Credit Suisse
Whirlpool price target raised to $103 from $90 at Credit Suisse
06/11/20 Oppenheimer
Roku price target raised to $140 from $135 at Oppenheimer
06/03/20 Stephens
Roku may be seeing pressure from Best Buy TCL TVs, says Stephens
06/03/20 SunTrust
New TVs at Best Buy present 'modest' new competition for Roku, says Suntrust
GILD Gilead
$74.56 /

+0.04 (+0.05%)

06/30/20 Wells Fargo
Remdesivir pricing 'a responsible public health decision,' says Wells Fargo
06/29/20 Piper Sandler
Piper says Gilead sale to HHS should make remdesivir opportunity 'more tangible'
06/29/20 RBC Capital
RBC says HIV, other franchises more critical drivers of Gilead than remdesivir
06/29/20 Piper Sandler
Gilead pricing for Remdesivir 'perfectly reasonable,' says Piper Sandler
ICPT Intercept
$46.66 /

-30.9 (-39.84%)

06/30/20 B. Riley FBR
Intercept selloff yesterday overdone, says B. Riley FBR
06/30/20 Baird
Intercept downgraded to Neutral following "surprise" FDA decision at Baird
06/30/20 BMO Capital
Intercept downgraded to Market Perform from Outperform at BMO Capital
06/30/20 UBS
Intercept downgraded to Neutral from Buy at UBS
HRTX Heron Therapeutics
$14.26 /

-5.555 (-28.04%)

06/29/20 JPMorgan
HTX-011 CRL 'a clear positive' for Pacira, says JPMorgan
06/29/20 Evercore ISI
Heron Therapeutics should be bought on CRL weakness, says Evercore ISI
05/27/20 Guggenheim
Guggenheim starts coverage of four pain treatment makers with two Buys
05/26/20 Guggenheim
Heron Therapeutics initiated with a Buy at Guggenheim
AMZN Amazon.com
$2,682.00 /

-11.16 (-0.41%)

06/30/20 Mizuho
Amazon.com price target raised to $3,100 from $2,550 at Mizuho
06/29/20 Monness Crespi
Amazon.com price target raised to $3,500 from $2,800 at Monness Crespi
06/26/20 Baird
Amazon acquiring Zoox could be 'game-changing,' says Baird
06/26/20 SunTrust
Etsy price target raised to $112 from $88 at SunTrust
AMC AMC Entertainment
$4.43 /

+0.27 (+6.49%)

06/30/20 Imperial Capital
AMC Entertainment price target lowered to $4 from $6 at Imperial Capital
06/29/20 Credit Suisse
Cinemark downgraded to Neutral from Outperform at Credit Suisse
06/29/20 Credit Suisse
AMC Entertainment downgraded to Underperform from Neutral at Credit Suisse
06/17/20 Citi
AMC Entertainment price target raised to $4 from $1 at Citi
IDEX Ideanomics
$2.06 /

+0.61 (+42.07%)

KNSA Kiniksa
$26.00 /

+2.96 (+12.85%)

06/29/20 Goldman Sachs
Kiniksa price target raised to $33 from $29 at Goldman Sachs
06/29/20 Wedbush
Kiniksa price target raised to $38 from $30 at Wedbush
04/01/20
Fly Intel: Top five analyst initiations
04/01/20 BofA
Kiniksa initiated with a Buy at BofA
BYND Beyond Meat
$131.52 /

-10.16 (-7.17%)

06/29/20
Fly Intel: Top five analyst downgrades
06/29/20 Barclays
Barclays double downgrades Beyond Meat to Underweight on restaurant closures
06/29/20 Barclays
Beyond Meat downgraded to Underweight from Overweight at Barclays
06/17/20 Credit Suisse
Beyond Meat price target raised to $142 from $90 at Credit Suisse
SBUX Starbucks
$73.50 /

+1.95 (+2.73%)

MSFT Microsoft
$198.49 /

+2.24 (+1.14%)

KO Coca-Cola
$44.35 /

+0.77 (+1.77%)

KNSA Kiniksa
$26.00 /

+2.96 (+12.85%)

ICPT Intercept
$46.66 /

-30.9 (-39.84%)

HRTX Heron Therapeutics
$14.26 /

-5.555 (-28.04%)

GILD Gilead
$74.56 /

+0.04 (+0.05%)

FB Facebook
$220.70 /

+4.84 (+2.24%)

F Ford
$6.02 /

+0.11 (+1.86%)

BYND Beyond Meat
$131.52 /

-10.16 (-7.17%)

BBY Best Buy
$86.31 /

+1.58 (+1.86%)

BA Boeing
$194.42 /

+24.51 (+14.43%)

AMZN Amazon.com
$2,682.00 /

-11.16 (-0.41%)

AMC AMC Entertainment
$4.43 /

+0.27 (+6.49%)

ADDYY Adidas
$0.00 /

+ (+0.00%)

  • 14
    May
  • 04
    Oct
  • 01
    Aug
SBUX Starbucks
$73.50 /

+1.95 (+2.73%)

MSFT Microsoft
$198.49 /

+2.24 (+1.14%)

KO Coca-Cola
$44.35 /

+0.77 (+1.77%)

IDEX Ideanomics
$2.06 /

+0.61 (+42.07%)

GILD Gilead
$74.56 /

+0.04 (+0.05%)

FB Facebook
$220.70 /

+4.84 (+2.24%)

F Ford
$6.02 /

+0.11 (+1.86%)

BYND Beyond Meat
$131.52 /

-10.16 (-7.17%)

BBY Best Buy
$86.31 /

+1.58 (+1.86%)

BA Boeing
$194.42 /

+24.51 (+14.43%)

AMZN Amazon.com
$2,682.00 /

-11.16 (-0.41%)

AMC AMC Entertainment
$4.43 /

+0.27 (+6.49%)

ADDYY Adidas
$0.00 /

+ (+0.00%)

SBUX Starbucks
$73.50 /

+1.95 (+2.73%)

MSFT Microsoft
$198.49 /

+2.24 (+1.14%)

KO Coca-Cola
$44.35 /

+0.77 (+1.77%)

KNSA Kiniksa
$26.00 /

+2.96 (+12.85%)

IDEX Ideanomics
$2.06 /

+0.61 (+42.07%)

ICPT Intercept
$46.66 /

-30.9 (-39.84%)

HRTX Heron Therapeutics
$14.26 /

-5.555 (-28.04%)

GILD Gilead
$74.56 /

+0.04 (+0.05%)

FB Facebook
$220.70 /

+4.84 (+2.24%)

F Ford
$6.02 /

+0.11 (+1.86%)

BBY Best Buy
$86.31 /

+1.58 (+1.86%)

BA Boeing
$194.42 /

+24.51 (+14.43%)

AMZN Amazon.com
$2,682.00 /

-11.16 (-0.41%)

AMC AMC Entertainment
$4.43 /

+0.27 (+6.49%)

ADDYY Adidas
$0.00 /

+ (+0.00%)

SBUX Starbucks
$73.50 /

+1.95 (+2.73%)

MSFT Microsoft
$198.49 /

+2.24 (+1.14%)

KO Coca-Cola
$44.35 /

+0.77 (+1.77%)

KNSA Kiniksa
$26.00 /

+2.96 (+12.85%)

IDEX Ideanomics
$2.06 /

+0.61 (+42.07%)

GILD Gilead
$74.56 /

+0.04 (+0.05%)

FB Facebook
$220.70 /

+4.84 (+2.24%)

F Ford
$6.02 /

+0.11 (+1.86%)

BYND Beyond Meat
$131.52 /

-10.16 (-7.17%)

BBY Best Buy
$86.31 /

+1.58 (+1.86%)

BA Boeing
$194.42 /

+24.51 (+14.43%)

AMZN Amazon.com
$2,682.00 /

-11.16 (-0.41%)

AMC AMC Entertainment
$4.43 /

+0.27 (+6.49%)

MSFT Microsoft
$198.49 /

+2.24 (+1.14%)

AMZN Amazon.com
$2,682.00 /

-11.16 (-0.41%)

Recommendations
Piper says Gilead sale to HHS should make remdesivir opportunity 'more tangible' » 14:16
06/29/20
06/29
14:16
06/29/20
14:16
GILD

Gilead

$74.59 /

+0.07 (+0.09%)

After Gilead announced…

After Gilead announced remdesivir pricing for developed countries and the U.S. Department of Health and Human Services announced that it has secured more than 500,000 treatment courses of the drug for American hospitals through September, Piper Sandler analyst Tyler Van Buren said the news "is not terribly surprising given the urgent need" for the drug, but added that "it should make the remdesivir opportunity all the more tangible to investors." Assuming a 5-day treatment course would result in $1.6B of gross sales, or over $1B in net sales, which will pay back some of the $1B investment Gilead is making by year-end, added Van Buren, who keeps an Overweight rating on Gilead shares.

ShowHide Related Items >><<
GILD Gilead
$74.59 /

+0.07 (+0.09%)

GILD Gilead
$74.59 /

+0.07 (+0.09%)

06/29/20 RBC Capital
RBC says HIV, other franchises more critical drivers of Gilead than remdesivir
06/29/20 Piper Sandler
Gilead pricing for Remdesivir 'perfectly reasonable,' says Piper Sandler
06/29/20 B. Riley FBR
Durect should be bought on weakness from Gilead termination, says B. Riley FBR
06/29/20 H.C. Wainwright
Durect thesis unchanged after Gilead termination, says H.C. Wainwright
GILD Gilead
$74.59 /

+0.07 (+0.09%)

GILD Gilead
$74.59 /

+0.07 (+0.09%)

GILD Gilead
$74.59 /

+0.07 (+0.09%)

GILD Gilead
$74.59 /

+0.07 (+0.09%)

Hot Stocks
HHS secures over 500,000 treatment courses of Remdesivir » 14:15
06/29/20
06/29
14:15
06/29/20
14:15
GILD

Gilead

$74.59 /

+0.07 (+0.09%)

, ABC

AmerisourceBergen

$99.35 /

+0.22 (+0.22%)

The Department of Health…

The Department of Health and Human Services announced an agreement to secure "large supplies" of Remdesivir for the United States from Gilead Sciences (GILD) through September, "allowing American hospitals to purchase the drug in amounts allocated by HHS and state health departments." HHS has secured more than 500,000 treatment courses of the drug for American hospitals through September, the agency said in a statement. This represents 100% of Gilead's projected production for July, 90% of production in August, and 90% of production in September, in addition to an allocation for clinical trials, it added.. A treatment course of remdesivir is, on average, 6.25 vials. Hospitals will receive the product shipped by AmerisourceBergen (ABC) and will pay no more than Gilead's wholesale acquisition price, which amounts to approximately $3,200 per treatment course, the HHS said. Reference Link

ShowHide Related Items >><<
GILD Gilead
$74.59 /

+0.07 (+0.09%)

ABC AmerisourceBergen
$99.35 /

+0.22 (+0.22%)

GILD Gilead
$74.59 /

+0.07 (+0.09%)

06/29/20 RBC Capital
RBC says HIV, other franchises more critical drivers of Gilead than remdesivir
06/29/20 Piper Sandler
Gilead pricing for Remdesivir 'perfectly reasonable,' says Piper Sandler
06/29/20 B. Riley FBR
Durect should be bought on weakness from Gilead termination, says B. Riley FBR
06/29/20 H.C. Wainwright
Durect thesis unchanged after Gilead termination, says H.C. Wainwright
ABC AmerisourceBergen
$99.35 /

+0.22 (+0.22%)

06/15/20 Morgan Stanley
Morgan Stanley upgrades AmerisourceBergen on opioid settlement potential
06/15/20 Morgan Stanley
AmerisourceBergen upgraded to Overweight from Equal Weight at Morgan Stanley
05/22/20 Wolfe Research
McKesson upgraded to Outperform from Peer Perform at Wolfe Research
05/18/20 Argus
Argus sees long term growth opportunities for AmerisourceBergen
GILD Gilead
$74.59 /

+0.07 (+0.09%)

ABC AmerisourceBergen
$99.35 /

+0.22 (+0.22%)

GILD Gilead
$74.59 /

+0.07 (+0.09%)

ABC AmerisourceBergen
$99.35 /

+0.22 (+0.22%)

GILD Gilead
$74.59 /

+0.07 (+0.09%)

ABC AmerisourceBergen
$99.35 /

+0.22 (+0.22%)

GILD Gilead
$74.59 /

+0.07 (+0.09%)

ABC AmerisourceBergen
$99.35 /

+0.22 (+0.22%)

On The Fly
Fly Intel: Wall Street's top stories at midday » 12:26
06/29/20
06/29
12:26
06/29/20
12:26
FB

Facebook

$217.43 /

+1.57 (+0.73%)

, SBUX

Starbucks

$72.74 /

+1.19 (+1.66%)

, KO

Coca-Cola

$44.33 /

+0.75 (+1.72%)

, GILD

Gilead

$75.10 /

+0.58 (+0.78%)

, TWTR

Twitter

$29.63 /

+0.58 (+2.00%)

, SNAP

Snap

$22.90 /

-0.16 (-0.69%)

, BA

Boeing

$180.14 /

+10.23 (+6.02%)

, ICPT

Intercept

$47.88 /

-29.68 (-38.27%)

, HRTX

Heron Therapeutics

$14.23 /

-5.585 (-28.19%)

, IDEX

Ideanomics

$2.18 /

+0.73 (+50.34%)

, BYND

Beyond Meat

$128.78 /

-12.9 (-9.11%)

, KNSA

Kiniksa

$27.86 /

+4.82 (+20.92%)

Stocks are rising in a…

Open Full Text

ShowHide Related Items >><<
TWTR Twitter
$29.63 /

+0.58 (+2.00%)

SNAP Snap
$22.90 /

-0.16 (-0.69%)

SBUX Starbucks
$72.74 /

+1.19 (+1.66%)

KO Coca-Cola
$44.33 /

+0.75 (+1.72%)

KNSA Kiniksa
$27.86 /

+4.82 (+20.92%)

IDEX Ideanomics
$2.18 /

+0.73 (+50.34%)

ICPT Intercept
$47.88 /

-29.68 (-38.27%)

HRTX Heron Therapeutics
$14.23 /

-5.585 (-28.19%)

GILD Gilead
$75.10 /

+0.58 (+0.78%)

FB Facebook
$217.43 /

+1.57 (+0.73%)

BYND Beyond Meat
$128.78 /

-12.9 (-9.11%)

BA Boeing
$180.14 /

+10.23 (+6.02%)

FB Facebook
$217.43 /

+1.57 (+0.73%)

06/29/20 JPMorgan
Facebook estimates not at risk from ad boycott, says JPMorgan
06/25/20 Baird
Facebook price target raised to $300 from $240 at Baird
06/24/20 Goldman Sachs
Facebook price target raised to $265 from $250 at Goldman Sachs
06/18/20 Morgan Stanley
Section 230 change likely a multi-year process, says Morgan Stanley
SBUX Starbucks
$72.74 /

+1.19 (+1.66%)

06/24/20 JPMorgan
Starbucks price target raised to $78 from $73 at JPMorgan
06/15/20
Fly Intel: Top five analyst initiations
06/15/20 Atlantic Equities
Starbucks initiated with an Overweight at Atlantic Equities
06/11/20
Fly Intel: Top five analyst downgrades
KO Coca-Cola
$44.33 /

+0.75 (+1.72%)

06/17/20 Jefferies
Nestle home-office water business would be a fit for Primo Water, says Jefferies
05/28/20 Credit Suisse
Boston Beer downgraded to Neutral on valuation at Credit Suisse
05/18/20 Guggenheim
Guggenheim raises PepsiCo to 'Best Idea' in Food and Beverage, ups target
05/11/20 Citi
Monster Beverage downgraded to Neutral from Buy at Cit
GILD Gilead
$75.10 /

+0.58 (+0.78%)

06/29/20 RBC Capital
RBC says HIV, other franchises more critical drivers of Gilead than remdesivir
06/29/20 Piper Sandler
Gilead pricing for Remdesivir 'perfectly reasonable,' says Piper Sandler
06/29/20 B. Riley FBR
Durect should be bought on weakness from Gilead termination, says B. Riley FBR
06/29/20 H.C. Wainwright
Durect thesis unchanged after Gilead termination, says H.C. Wainwright
TWTR Twitter
$29.63 /

+0.58 (+2.00%)

06/22/20 Citi
Twitter price target raised to $36 from $30 at Citi
06/16/20 JPMorgan
JPMorgan continues to prefer Facebook, Snap in online advertising
SNAP Snap
$22.90 /

-0.16 (-0.69%)

06/26/20 Wells Fargo
Snap price target raised to $28 from $20 at Wells Fargo
06/25/20 Citi
Citi recommends pair trade of buying Omnicom, selling Snap
06/24/20 Wedbush
Snap price target raised to $16 from $12.25 at Wedbush
BA Boeing
$180.14 /

+10.23 (+6.02%)

06/26/20
Fly Intel: Top five analyst downgrades
06/26/20 RBC Capital
Spirit AeroSystems initiated with an Outperform at RBC Capital
06/26/20 Bernstein
Boeing downgraded to Market Perform from Outperform at Bernstein
06/25/20
Fly Intel: Top five analyst downgrades
ICPT Intercept
$47.88 /

-29.68 (-38.27%)

06/29/20 RBC Capital
RBC downgrades Intercept on 'fundamental questioning' of drug
06/29/20 RBC Capital
Intercept downgraded to Sector Perform from Outperform at RBC Capital
06/29/20 Canaccord
Intercept downgraded to Hold from Buy at Canaccord after receiving FDA CRL
06/29/20 Canaccord
Intercept downgraded to Hold from Buy at Canaccord
HRTX Heron Therapeutics
$14.23 /

-5.585 (-28.19%)

06/29/20 JPMorgan
HTX-011 CRL 'a clear positive' for Pacira, says JPMorgan
06/29/20 Evercore ISI
Heron Therapeutics should be bought on CRL weakness, says Evercore ISI
05/27/20 Guggenheim
Guggenheim starts coverage of four pain treatment makers with two Buys
05/26/20 Guggenheim
Heron Therapeutics initiated with a Buy at Guggenheim
IDEX Ideanomics
$2.18 /

+0.73 (+50.34%)

BYND Beyond Meat
$128.78 /

-12.9 (-9.11%)

06/29/20
Fly Intel: Top five analyst downgrades
06/29/20 Barclays
Barclays double downgrades Beyond Meat to Underweight on restaurant closures
06/29/20 Barclays
Beyond Meat downgraded to Underweight from Overweight at Barclays
06/17/20 Credit Suisse
Beyond Meat price target raised to $142 from $90 at Credit Suisse
KNSA Kiniksa
$27.86 /

+4.82 (+20.92%)

06/29/20 Goldman Sachs
Kiniksa price target raised to $33 from $29 at Goldman Sachs
06/29/20 Wedbush
Kiniksa price target raised to $38 from $30 at Wedbush
04/01/20
Fly Intel: Top five analyst initiations
04/01/20 BofA
Kiniksa initiated with a Buy at BofA
TWTR Twitter
$29.63 /

+0.58 (+2.00%)

SNAP Snap
$22.90 /

-0.16 (-0.69%)

SBUX Starbucks
$72.74 /

+1.19 (+1.66%)

KO Coca-Cola
$44.33 /

+0.75 (+1.72%)

KNSA Kiniksa
$27.86 /

+4.82 (+20.92%)

ICPT Intercept
$47.88 /

-29.68 (-38.27%)

HRTX Heron Therapeutics
$14.23 /

-5.585 (-28.19%)

GILD Gilead
$75.10 /

+0.58 (+0.78%)

FB Facebook
$217.43 /

+1.57 (+0.73%)

BYND Beyond Meat
$128.78 /

-12.9 (-9.11%)

BA Boeing
$180.14 /

+10.23 (+6.02%)

  • 14
    May
  • 04
    Oct
  • 01
    Aug
TWTR Twitter
$29.63 /

+0.58 (+2.00%)

SNAP Snap
$22.90 /

-0.16 (-0.69%)

SBUX Starbucks
$72.74 /

+1.19 (+1.66%)

KO Coca-Cola
$44.33 /

+0.75 (+1.72%)

IDEX Ideanomics
$2.18 /

+0.73 (+50.34%)

GILD Gilead
$75.10 /

+0.58 (+0.78%)

FB Facebook
$217.43 /

+1.57 (+0.73%)

BYND Beyond Meat
$128.78 /

-12.9 (-9.11%)

BA Boeing
$180.14 /

+10.23 (+6.02%)

SNAP Snap
$22.90 /

-0.16 (-0.69%)

SBUX Starbucks
$72.74 /

+1.19 (+1.66%)

KO Coca-Cola
$44.33 /

+0.75 (+1.72%)

KNSA Kiniksa
$27.86 /

+4.82 (+20.92%)

IDEX Ideanomics
$2.18 /

+0.73 (+50.34%)

ICPT Intercept
$47.88 /

-29.68 (-38.27%)

GILD Gilead
$75.10 /

+0.58 (+0.78%)

FB Facebook
$217.43 /

+1.57 (+0.73%)

BYND Beyond Meat
$128.78 /

-12.9 (-9.11%)

BA Boeing
$180.14 /

+10.23 (+6.02%)

TWTR Twitter
$29.63 /

+0.58 (+2.00%)

SNAP Snap
$22.90 /

-0.16 (-0.69%)

SBUX Starbucks
$72.74 /

+1.19 (+1.66%)

KO Coca-Cola
$44.33 /

+0.75 (+1.72%)

KNSA Kiniksa
$27.86 /

+4.82 (+20.92%)

IDEX Ideanomics
$2.18 /

+0.73 (+50.34%)

GILD Gilead
$75.10 /

+0.58 (+0.78%)

FB Facebook
$217.43 /

+1.57 (+0.73%)

BYND Beyond Meat
$128.78 /

-12.9 (-9.11%)

BA Boeing
$180.14 /

+10.23 (+6.02%)

Recommendations
RBC says HIV, other franchises more critical drivers of Gilead than remdesivir » 12:01
06/29/20
06/29
12:01
06/29/20
12:01
GILD

Gilead

$75.14 /

+0.62 (+0.83%)

After Gilead announced…

After Gilead announced global pricing for its coronavirus treatment remdesivir at $390 per vial, and set the price higher for commercial payers, RBC Capital analyst Brian Abrahams said he believes the blended U.S. price accounting for discounts across reimbursers will likely come in at $2,340 per treatment course. He believes the pricing is generally in line with expectations, although the analyst notes it is below "some recent more bullish estimates." While he estimates that this pricing and his other assumptions would imply revenue potential of about $2.3B in 2020 from remdesivir, Abrahams believes the fundamental value creation opportunity for remdesivir remains limited. The analyst, who continues to view Gilead's share price as undervaluing the company's strong HIV franchise and emerging pipeline, keeps an Outperform rating on the stock.

ShowHide Related Items >><<
GILD Gilead
$75.14 /

+0.62 (+0.83%)

GILD Gilead
$75.14 /

+0.62 (+0.83%)

06/29/20 Piper Sandler
Gilead pricing for Remdesivir 'perfectly reasonable,' says Piper Sandler
06/29/20 B. Riley FBR
Durect should be bought on weakness from Gilead termination, says B. Riley FBR
06/29/20 H.C. Wainwright
Durect thesis unchanged after Gilead termination, says H.C. Wainwright
06/10/20 SunTrust
Arcus Biosciences price target raised to $45 from $22 at SunTrust
GILD Gilead
$75.14 /

+0.62 (+0.83%)

GILD Gilead
$75.14 /

+0.62 (+0.83%)

GILD Gilead
$75.14 /

+0.62 (+0.83%)

GILD Gilead
$75.14 /

+0.62 (+0.83%)

Recommendations
Gilead pricing for Remdesivir 'perfectly reasonable,' says Piper Sandler » 09:12
06/29/20
06/29
09:12
06/29/20
09:12
GILD

Gilead

$74.52 /

-0.94 (-1.25%)

Piper Sandler analyst…

Piper Sandler analyst Tyler Van Buren views the Remdesivir pricing for developed countries, which is $390 per vial or $520 for private insurance in the U.S, as "perfectly reasonable" and within expectations. Essentially, in the U.S., the vast majority of patients will be on a five-day treatment course, which will cost anywhere from $2,300-3,100, Van Buren tells investors in a research note. The analyst believes the range "seems reasonable considering that the value of early discharge is $12,000 per the US government." Van Buren keeps an Overweight rating on Gilead Sciences with a $90 price target.

ShowHide Related Items >><<
GILD Gilead
$74.52 /

-0.94 (-1.25%)

GILD Gilead
$74.52 /

-0.94 (-1.25%)

06/29/20 B. Riley FBR
Durect should be bought on weakness from Gilead termination, says B. Riley FBR
06/29/20 H.C. Wainwright
Durect thesis unchanged after Gilead termination, says H.C. Wainwright
06/10/20 SunTrust
Arcus Biosciences price target raised to $45 from $22 at SunTrust
06/08/20 SVB Leerink
Gilead unlikely to be responsive to AstraZeneca's outreach, says SVB Leerink
GILD Gilead
$74.52 /

-0.94 (-1.25%)

GILD Gilead
$74.52 /

-0.94 (-1.25%)

GILD Gilead
$74.52 /

-0.94 (-1.25%)

GILD Gilead
$74.52 /

-0.94 (-1.25%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.